Loading news...
Acuitas Investments LLC purchased a new position in Treace Medical Concepts, Inc. (NASDAQ: TMCI) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 301,100 shares of the company's stock, valued at approximately $2,020,000. Treace Medical Concepts comprises 0.9% of Acuitas Investments LLC's
Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results.
PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology.
Shares of Treace Medical Concepts, Inc. (NASDAQ: TMCI - Get Free Report) traded down 0.8% on Friday. The stock traded as low as $2.41 and last traded at $2.42. 692,875 shares were traded during mid-day trading, a decline of 15% from the average session volume of 810,528 shares. The stock had previously closed at $2.44.
New 5-Year Agreement Provides Continued Financial Strength & Flexibility New 5-Year Agreement Provides Continued Financial Strength & Flexibility
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether certain officers and directors of Quantum Computing Inc. (NASDAQ: QUBT), Quanex Building Products Corporation (NYSE: NX), Treace Medical Concepts, Inc. (NASDAQ: TMCI), and BigBear. ai Holdings, Inc.
Treace Medical Concepts, Inc. ( TMCI ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Trip Taylor John Treace - Founder, Chairman & CEO Mark Hair - Chief Financial Officer Conference Call Participants Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Marie Thibault - BTIG, LLC, Research Division Jayna Renee Francis - UBS Investment Bank, Research Division Presentation Trip Taylor Good afternoon, everyone, and welcome to our third quarter 2025 earnings conference call. Participating from the company today will be John Treace, Chief Executive Officer; and Mark Hair, Chief Financial Officer.
PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will participate in the following upcoming investor conferences.
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.25 per share a year ago.
Y Intercept Hong Kong Ltd lifted its stake in shares of Treace Medical Concepts, Inc. (NASDAQ: TMCI) by 645.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 232,413 shares of the company's stock after buying an additional 201,252 shares during the
Treace Medical Concepts (NASDAQ: TMCI - Get Free Report) is projected to issue its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $49.5970 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2025 earningoverview
PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, November 6, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2025 in Savannah, Georgia from September 10-13, 2025.
Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Investor Day Call September 3, 2025 9:00 AM EDT Company Participants John Treace - Founder, Chairman & CEO Sean Scanlan - Chief Innovation Officer Conference Call Participants William DeCarbo Mark Easley Holly Johnson Jonathan Kaplan Ryan Zimmerman - BTIG, LLC, Research Division Richard Newitter - Truist Securities, Inc., Research Division Arthur Weise Danielle Antalffy - UBS Investment Bank, Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Anton Heldmann - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation John Treace Founder, Chairman & CEO Good morning, everybody. We're going to go ahead and get started.
Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John T. Treace - Founder, Chairman & CEO Mark L.
Treace Medical (TMCI) Q2 Revenue Up 7%
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.34 per share a year ago.
PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the second quarter ended June 30, 2025.
PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced plans to host an investor day at 9:00 am E.T. on September 3, 2025, in New York, New York. The event will include presentations by members of management and experienced surgeon users, highlighting their experiences with the expanded technology portfolio.